Scarica l'app Stockscreener
2.11
0.96%
0.02
Precedente Chiudi:
$2.09
Aprire:
$2.08
Volume 24 ore:
885.97K
Relative Volume:
0.26
Capitalizzazione di mercato:
$366.68M
Reddito:
$250.00K
Utile/perdita netta:
$-24.15M
Rapporto P/E:
-1.9801
EPS:
-1.0656
Flusso di cassa netto:
$-12.40M
1 W Prestazione:
+11.35%
1M Prestazione:
+1.44%
6M Prestazione:
+28.66%
1 anno Prestazione:
+140.21%
Intervallo 1D:
$2.05
$2.1175
Intervallo di 1 settimana:
$1.89
$2.15
Portata 52W:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.11 | 352.77M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-26 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-09 | Iniziato | B. Riley Securities | Buy |
| 2025-12-29 | Iniziato | Piper Sandler | Overweight |
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PALI|Palisade Bio Inc|Price:1.950|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
Palisade Bio Inc (PALI) Institutional Confidence - TradingKey
Palisade Bio Inc. (PALI) Dips 3.5% as Shares Test Key Support at $1.85Reversal Setup Alerts - dars.gov.et
Palisade Bio Inc (PALI) Cash Flow - TradingKey
Palisade Bio Inc (PALI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Benzinga
PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ) - Seeking Alpha
Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com India
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com UK
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com - Investing.com South Africa
Palisade Bio chief medical officer Jones sells $106,535 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock - Investing.com
Palisade Bio CEO, CFO Finley sells $303k in stock - Investing.com
Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys - Stock Titan
[Form 4] PALISADE BIO, INC. Insider Trading Activity - Stock Titan
Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax - Stock Titan
Stifel Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Insider Spends US$59k Buying More Shares In Palisade Bio - simplywall.st
Palisade Bio Inc. (PALI) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D FocusPre-Earnings Drift - dars.gov.et
Form 144 PALISADE BIO For: 7 July By Investing.com - Investing.com Nigeria
[144] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock By Investing.com - Investing.com South Africa
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palisade Bio Inc Azioni (PALI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baltera Robert Jr. | Director |
Jul 08 '26 |
Buy |
1.99 |
20,000 |
39,798 |
436,904 |
| Baltera Robert Jr. | Director |
Jul 07 '26 |
Buy |
2.03 |
30,000 |
61,044 |
416,904 |
| Baltera Robert Jr. | Director |
Jul 06 '26 |
Buy |
2.05 |
20,000 |
41,040 |
386,904 |
| Jones Mitchell Lawrence | Chief Medical Officer |
Jul 07 '26 |
Sale |
2.05 |
51,880 |
106,536 |
94,009 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Option Exercise |
0.70 |
133 |
93 |
217,688 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Sale |
2.07 |
146,798 |
303,343 |
217,555 |
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):